… to find the needle faster. In-silico drug repurposing studies are a fast and efficient way to screen for new drug candidates to combat new or rare diseases. We also provide in-silico predictions of unexpected drug side effects before elaborated clinical trials for new drug discovery in the pharmaceutical and healthcare industries.
Since the onset of the COVID-19 pandemic, we have been able to help shed more light on the nature of the SARS-CoV-2 virus through a series of studies.
Read more here.
In a recent structural bioinformatics approach, we gained new insights into the impact of amino acid exchanges on the affinity of the spike RBD for the human receptor hACE2.
Read more here: Structural bioinformatics analysis of SARS-CoV-2 variants reveals higher hACE2 receptor binding affinity for Omicron B.1.1.529 spike RBD compared to wild type reference
Durmaz, V., Köchl, K., Krassnigg, A. et al., Sci Rep 12, 14534 (2022).
Even though our platforms are ready-to-use, we do not believe in one-fits-all solutions. Tailor-made software solutions help you optimize your R&D pipeline and redefine how you solve problems. Our developers are committed to eliminating bottlenecks and adapting our CatalophoreTM platform to your needs. Our AI-driven technologies learn and grow with your projects and are customizable to your goals.